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Synergistic interactions were observed between CIs and antifungal agents against 53 (90%) of 59 Cryptococ-
cus neoformans isolates from solid organ transplant recipients with cryptococcosis and may account for better
outcomes in patients with cryptococcosis receiving these immunosuppressive agents.
Cryptococcosis occurs in 0.3 to 5% and an average of 3% of
solid organ transplant (SOT) recipients (12, 13, 18, 23). Dis-
semination beyond the pulmonary focus and central nervous
system (CNS) involvement have been documented in 52 to
61% of these patients (12, 13, 18, 23). Mortality rates in trans-
plant recipients with cryptococcosis typically range from 15 to
20% and approach 40% in those with CNS infection (1, 12, 13,
18, 23).
Calcineurin inhibitor (CI)-based regimens are the mainstay
of modern antirejection therapy in SOT recipients. Further-
more, CIs have been independently associated with improved
outcomes in SOT recipients with cryptococcosis (19, 21). This
beneficial effect of CI agents is in part considered to be attrib-
utable to their in vitro antifungal activity against Cryptococcus
neoformans (8, 11, 17). The calcineurin pathway plays a vital
role in cellular morphogenesis and virulence in C. neoformans
(7). Inhibitors of this signaling pathway such as tacrolimus
(FK506) and cyclosporine (CsA) target not only the mamma-
lian but also the fungal homologs of calcineurin (11). C. neo-
formans also possesses TOR kinases, and their inhibitors, such
as rapamycin, impair cell proliferation via the nutrient-sensing
pathway of this yeast (5, 6). Additionally, in vitro data obtained
with laboratory strains have shown synergistic interactions be-
tween the immunosuppressive and antifungal agents against
pathogenic fungi, including C. neoformans (10, 14, 15). There
are no clinical studies, however, that have determined the
relevance of these in vitro findings. To this end, we examined
the magnitude of in vitro interactions between CI agents or
rapamycin and antifungals against C. neoformans clinical iso-
lates and their correlation with the treatment outcomes of a
recent cohort of SOT recipients with cryptococcosis.
(The data presented here were previously presented in part
at the 47th Interscience Conference on Antimicrobial Agents
and Chemotherapy, Chicago, IL, 17 to 20 September 2007.)
The study population was derived from a large cohort of
SOT recipients with cryptococcosis who were studied prospec-
tively between 1999 and 2006 (21). A total of 74 patients from
whom C. neoformans isolates were available made up the pa-
tient population in the present study. C. neoformans infection
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was defined in accordance with the criteria set forth by the
European Organization for Research and Treatment in Can-
cer and the Mycoses Study Group (3). Organ sites involved
were classified as CNS, pulmonary, skin, soft tissue, osteoar-
ticular, or other (12, 19). Disseminated infection was defined
as CNS disease, fungemia, or involvement of two or more
noncontiguous organs (12, 19).
In vitro drug interactions between CIs (tacrolimus or FK506
and CsA), rapamycin, and antifungal agents (amphotericin B
[AmB] and fluconazole) against clinical isolates of C. neofor-
mans were assessed (blinded to clinical data) by using the CLSI
(formerly NCCLS) M38-A method modified for broth microdi-
lution checkerboard testing as previously reported (19, 20, 22).
In vitro MICs of the antifungal agents (AmB and fluconazole)
and immunosuppressive agents (tacrolimus, CsA, and siroli-
mus) alone or in combination were determined by using con-
centrations of 0.125 to 64 g/ml for fluconazole, 0.03 to 16
g/ml for AmB, and 0.04 to 25 g/ml for the three immuno-
suppressive agents (22). MICs were determined at 37°C by
using RPMI 1640 medium and 2% glucose buffered to pH 7.
Sterile normal saline was used as the solvent for the antifungal
agents, and dimethyl sulfoxide (DMSO) was used as the sol-
vent for the immunosuppressant drugs; the stock solution was
prepared at 100 times the highest concentration tested and
stored at 20°C. The final concentration was prepared from
the antifungals and the immunosuppressant stock solution in
RPMI plus 2% glucose. The final concentration of DMSO in
each well was 0.1% or less. Before testing, all isolates were
subcultured in liquid YPD medium to ensure optimal growth
characteristics. Stock suspensions were prepared in sterile nor-
mal saline and adjusted to yield a final inoculum concentration
of 1  106 to 5  106 cells/ml of stock solution. The stock
solution was then diluted 1:50 in RPMI culture medium to
obtain the final test inoculum (dilution of 1  104 to 5  104
cells/ml). Two well-characterized Candida isolates (Candida
albicans ATCC 90028 and Candida parapsilosis ATCC 22019)
were tested in parallel with each checkerboard plate as quality
control isolates (4).
Drug interactions were defined as synergistic, additive, or
antagonistic on the basis of the fractional inhibitory concen-
tration (FIC) index. The FIC index was considered to be the
sum of the FICs of each of the drugs and defined as the MIC
of the drug used in the combination divided by the MIC of the
drug when used alone. Drug interactions were considered as
synergistic if the lowest FIC index was 0.5, additive (i.e., no
interaction) if the lowest FIC index was 0.5 and 4, and
antagonistic if the highest FIC index was 4 (16).
Intercooled Stata 9.2 (StataCorp LP, College Station, TX)
was used for statistical analysis. The Fisher exact test was used
to compare categorical data. The end point was survival at 90
days. A logistic model was used to examine the effects of an
immunosuppressant regimen on survival at 90 days. Factors
added to the model were those known to contribute to a poor
prognosis in this cohort of patients (renal failure and dissem-
inated infection) as previously reported (19).
The MICs of AmB for the cryptococcal isolates ranged from
0.25 to 4 g/ml (mean, 1 g/ml), and those of fluconazole
ranged from 4 to 64 g/ml (mean, 16 g/ml). The mean MICs
of fluconazole were 17 g/ml for isolates from the recipients of
tacrolimus, 8 g/ml for the recipients of CsA, and 15.3 g/ml
for isolates from non-CI recipients (P  0.96). A synergistic
interaction of AmB with tacrolimus was found for 67 (90%) of
the 74 isolates, with CsA for 65/73 (89%), and with rapamycin
for 67/73 (92%); one isolate was unavailable for CsA and
rapamycin testing (Table 1). AmB interactions with these im-
munosuppressants were additive for the rest of the isolates and
antagonistic for none (Table 1). The MICs for quality control
strains were in agreement with the published ranges for each
drug; i.e., those of AmB were 0.25 to 2 g/ml, and those of
fluconazole were 0.12 to 1 g/ml (4).
Of 31 patients who received tacrolimus and AmB, 30 (97%)
yielded C. neoformans isolates against which these two drugs
showed synergy; 25 (83%) of these 30 patients survived (Table
2). CsA and AmB had synergistic interactions against the iso-
lates from seven (87%) of the patients who received those
drugs; the survival of these patients is shown in Table 2. The
interaction of immunosuppressive agents and fluconazole
against C. neoformans isolates is depicted in Table 1. Of 14
TABLE 1. Interactions of AmB or fluconazole with
immunosuppressive agents versus
C. neoformans isolates
Drug combination Median FICindex (range)
Synergistic
interactiona
Additive
interactiona
AmB  tacrolimus 0.25 (0.030–2) 67/74 (90) 7/74 (10)
AmB  CsA 0.12 (0.030–1) 65/73b (89) 9/73 (11)
AmB  rapamycin 0.12 (0.30–1) 67/73b (92) 7/73 (8)
Fluconazole 
tacrolimus
0.25 (0.03–1) 61/74 (82) 13/74 (17)
Fluconazole  CsA 0.125 (0.031–1) 69/74 (93) 5/74 (7)
Fluconazole 
rapamycin
0.125 (0.007–1) 71/74 (96) 3/74 (4)
a Data represent the number of patients whose isolates yielded the stated
interaction/total number (percentage) of patients whose isolates were tested.
None of the drugs demonstrated antagonism with any of the isolates.
b The isolate from one patient could not be tested.
TABLE 2. Outcomes (90-day survival) of patients stratified by the
immunosuppressive and antifungal agents received
Drug combination (n)a
Survivala in CI recipients
when drugs were:
Survivala of
non-CI
recipientsSynergistic Additive
Tacrolimus  AmB (31) 25/30 (83) 1/1 (100)
CsA  AmB (8) 7/7 (100) 1/1 (100)
Non-CI  AmB (9) 5/9 (56)
Tacrolimus  fluconazole
(14)
10/10 (100) 4/4 (100)
CsA  fluconazole (3) 3/3 (100)
Non-CI  fluconazole (4) 3/4 (75)
Any CI (56) 45/50 (90) 6/6 (100)
Any non-CI (13) 8/13 (62)
Total (69) 45/50 (90) 6/6 (100) 8/13 (62)
a Each value in parentheses is the number of patients who received the drug
combination.
b Data are presented for 69 of the 74 study patients; 2 patients who received
a CI were not treated (diagnosed at autopsy), and 3 received an antifungal agent
other than AmB or fluconazole as therapy for cryptococcosis.
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patients who received tacrolimus and fluconazole, 10 (71%)
had isolates against which the drugs demonstrated synergy and
4 (29%) had isolates against which this drug combination
showed additive interactions. The outcomes of these patients,
as well as those of patients who received CsA and fluconazole,
are shown in Table 2.
The survival at 90 days of the recipients of CIs treated with
AmB or fluconazole was 91% (51/56), compared to 61.5%
(8/13) for the recipients of non-CI agents who also received the
same antifungal agents (P  0.020). Of 10 patients who died,
9 received an AmB-based antifungal regimen as induction
therapy for cryptococcosis for a median of 17 days (range, 5 to
34 days) and 1 received fluconazole. When adjusted for factors
portending a poor outcome (renal failure and disseminated
infection), the odds ratio for the survival of patients receiving
a CI compared to those who received non-CIs was 6.19 (95%
confidence interval, 1.3 to 34.9; P  0.018). In this model, the
odds ratio for the survival of patients with renal failure was
0.24 (95% confidence interval, 0.04 to 1.24; P  0.09) and that
for those with disseminated infection was 0.15 (95% confi-
dence interval, 0.01 to 1.63; P  0.12). Mortality in the recip-
ients of CIs was too low to compare the outcomes of patients
whose isolates yielded synergistic versus nonsynergistic inter-
action; 10% (5/50) of the patients with isolates against which
the drugs demonstrated synergy and 0% (0/6) of those with
isolates against which they did not show synergy died (P 
0.99).
Transplant recipients are unique hosts in that the immuno-
suppressants used in these patients have shown synergism with
antifungal agents against several pathogenic yeasts and molds.
For example, although fluconazole exhibits largely fungistatic
activity against Candida, its combination with CIs is synergistic
and potently fungicidal against C. albicans, including strains
that are azole resistant (7, 15). The combination of tacrolimus
and fluconazole is also synergistic in vitro against C. neofor-
mans and resulted in an 30-fold decrease in the MIC of
tacrolimus and a 4-fold decrease in that of fluconazole for this
yeast (10). The synergistic activity of tacrolimus with flucon-
azole is mediated via inhibition of multidrug-resistant pumps
that export azoles from fungal cells and is independent of
calcineurin inhibition (10). Despite the fact that the FKS1
gene, which encodes -1,3-glucan synthase, is essential in C.
neoformans, the echinocandins have limited activity against this
yeast. However, the combination of caspofungin with tacroli-
mus is synergistic against C. neoformans (10). Synergism has
also been shown for CsA, tacrolimus, and rapamycin with AmB
or an echinocandin against Aspergillus fumigatus (14).
To our knowledge, our study is the first attempt to deter-
mine in vitro drug interactions of immunosuppressants with
antifungal agents in clinical isolates of C. neoformans and to
correlate these with outcome in SOT patients with cryptococ-
cosis. Synergy was observed between CIs and antifungal agents
against 90% of the C. neoformans isolates, and patients receiv-
ing CIs had significantly higher survival than non-CI recipients,
even when adjusted for renal failure and disseminated infec-
tion.
In the absence of prior exposure to the azoles, the MICs of
fluconazole against cryptococcal isolates typically range from 1
to 4 g/ml (2, 9). The median MIC of fluconazole against the
isolates in our study was 16 g/ml. Nevertheless, these strains
demonstrated synergy with the CI agents. The relatively high
MICs of fluconazole against the cryptococcal isolates, despite
the fact that only 1 of the 74 patients in our study had previ-
ously received fluconazole, raises the possibility that immuno-
suppressive drugs could potentially influence susceptibility to
the azole antifungal agents or the existence of yeast strains with
altered susceptibility due to as-yet-unknown factors.
Our study has limitations that deserve to be acknowledged.
Given a small number of patients receiving a non-CI agent-
based regimen, comparison of these patients with the recipi-
ents of CIs must be done with caution. We note that a non-
CI-based regimen was used as the standard of care and was not
due to noncompliance with the CIs. Second, since none of the
isolates showed antagonism, a meaningful comparison could
not be conducted between patients with isolates against which
the drugs showed synergistic versus antagonistic interactions.
Finally, we were unable to correlate synergy with time to cul-
ture negativity, decline in antigen titers, or fungus-attributable
mortality.
Improved outcomes in transplant recipients in the modern
immunosuppressive era are due largely to a lower overall risk
of rejection and greater graft survival. It is, however, plausible
that in concert with conventional antifungal agents, the unique
antifungal attributes of immunosuppressive agents potentially
contribute to better outcomes in transplant recipients with
opportunistic mycoses. Our findings raise the possibility that
outcomes in transplant recipients with invasive mycoses may be
further optimized by developing more potent inhibitors of fun-
gal signaling pathways.
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